Literature DB >> 1696178

Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator.

J L Heckel1, E P Sandgren, J L Degen, R D Palmiter, R L Brinster.   

Abstract

Spontaneous intestinal and intra-abdominal bleeding was observed in a high percentage of newborn transgenic mice carrying the murine urokinase-type plasminogen activator (uPA) gene linked to the albumin enhancer/promoter. These hemorrhagic events were directly related to transgene expression in the liver and the development of high plasma uPA levels. Two lines were established from surviving founder mice that displayed multigenerational transmission of the bleeding phenotype. Fatal hemorrhaging developed between 3 and 84 hr after birth in about half of the transgenic offspring of these lines; transgenic pups that did not bleed nevertheless passed the phenotype to their young. The phenotypic variability could not be explained by differences in transgene expression. All transgenic neonates were severely hypofibrinogenemic and displayed loss of clotting function that extended beyond the risk period for bleeding. These mice provide a means of studying the pathophysiology of plasminogen hyperactivation and evaluating therapeutic protocols designed to prevent bleeding.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696178     DOI: 10.1016/0092-8674(90)90010-c

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  67 in total

1.  Cellular origin of regenerating parenchyma in a mouse model of severe hepatic injury.

Authors:  K M Braun; E P Sandgren
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  Animal models for studying hepatitis C and alcohol effects on liver.

Authors:  David F Mercer
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

3.  Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment.

Authors:  Karl-Dimiter Bissig; Stefan F Wieland; Phu Tran; Masanori Isogawa; Tam T Le; Francis V Chisari; Inder M Verma
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

4.  New horizons for studying human hepatotropic infections.

Authors:  Ype P de Jong; Charles M Rice; Alexander Ploss
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

5.  Higher Serum Alanine Transaminase Levels in Male Urokinase-Type Plasminogen Activator-Transgenic Mice Are Associated With Improved Engraftment of Hepatocytes but not Liver Sinusoidal Endothelial Cells.

Authors:  Marina E Fomin; Ashley I Beyer; Jean Publicover; Kai Lu; Sonia Bakkour; Graham Simmons; Marcus O Muench
Journal:  Cell Med       Date:  2016-11-23

6.  Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo.

Authors:  A Lieber; M J Vrancken Peeters; L Meuse; N Fausto; J Perkins; M A Kay
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

7.  A novel animal model for in vivo study of liver cancer metastasis.

Authors:  Shinsuke Fujiwara; Hikaru Fujioka; Chise Tateno; Ken Taniguchi; Masahiro Ito; Hiroshi Ohishi; Rie Utoh; Hiromi Ishibashi; Takashi Kanematsu; Katsutoshi Yoshizato
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

8.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

9.  An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice.

Authors:  Martha J Harding; Christin M Lepus; Thomas F Gibson; Benjamin R Shepherd; Scott A Gerber; Morven Graham; Frank X Paturzo; Christoph Rahner; Joseph A Madri; Alfred L M Bothwell; Brett D Lindenbach; Jordan S Pober
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 10.  Towards a small animal model for hepatitis C.

Authors:  Alexander Ploss; Charles M Rice
Journal:  EMBO Rep       Date:  2009-10-16       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.